// App-Quantinova.ai

621 : A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers

Researchers

Presenter

  • Patrick van Berkel

Principal Investigators

  • Francesca Zammarchi

Medical Centers

  • ADC Therapeutics, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Interleukin-2

  • Regulatory T cells

Drug/Treatment

  • Interleukin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved